Acme Generics
Sourav Sharma is a seasoned Human Resources and Talent Acquisition Specialist with extensive experience in recruitment and selection strategies. Currently employed at Acme Generics since January 2024, Sourav is focused on talent acquisition, vendor management, and database management, ensuring timely filling of positions and maintaining interactions with candidates and staffing partners. Previous experience includes a role at Apolis where Sourav utilized ATS Job Diva for sourcing candidates from various job portals. At IMCS Group, responsibilities involved full life cycle recruiting and analyzing client requirements. Earlier experience at Axis Bank as a Management Trainee involved data analysis for projects related to digital banking and GST awareness. Sourav holds an MBA in Finance and HR from Central University of Himachal Pradesh and a Bachelor of Commerce from Himachal Pradesh University.
This person is not in any teams
This person is not in any offices
Acme Generics
Acme is a leading provider of Oral Solid and Sterile Dosage form Contract Manufacturing and Development services to the pharmaceutical industry. Acme began its journey in 2005 and in a decade has transformed into a trusted partner and a complete solution provider, having expanded into niche segments of Oral Hormones both Sex Hormones and Levothyroxine along with General Injectables both Liquids and Lyophilized, catering through three state of the art manufacturing facilities. Today it employs more than 1500 highly- skilled workforce in its facilities which are located in Northern India, the facilities are spread over an area of approx 500,000 sq ft having a capacity of 15 Billion Tablets, 5 Billion Capsules and 42 Million Ampoules / Vials. In our journey over the past decade we have been audited and approved by various international regulatory agencies like USFDA, UKMHRA, EU-GMP- Hungary, ANVISA, PICS-Ukraine, INVIMA, WHO-Geneva, Phillippines, Vietnam, TFDA, Nepal, NAFDACNigeria, Niger, NDA Uganda, FDA Ghana, PPB Kenya, DDA Nepal, DDF Cambodia, Senegal, Sierra Leone, US FDA filing planned for Q1, 2018 and UL for 21CFR Parts 210 & 211 as we continue our journey towards building a sustainable future we have audits lined by US FDA* in 2018